Véronique Pomi-Schneiter stands down as BioSenic's Deputy CEO
17 September 2024 - 7:00AM
UK Regulatory
Véronique Pomi-Schneiter stands down as BioSenic's Deputy CEO
PRIVILEGED INFORMATION
Mont-Saint-Guibert, Belgium, September
17, 2024 7.00pm CEST – BioSenic
(Euronext Brussels and Paris: BIOS), the clinical
stage company specializing in serious autoimmune and inflammatory
diseases, today announces that Véronique Pomi-Schneiter resignes
for personal reasons as Deputy CEO of BioSenic. Véronique
Pomi-Schneiter will fully assist in the transition process and
continue to serve as non-executive member of the board of directors
of BioSenic, as well as an executive member of the board of
directors (i.e., the strategic committee) of its subsidiary,
Medsenic SAS.
Prof. François Rieger, BioSenic CEO and
Chairman of the Board, declared: “We wish a full
recovery of health for Véronique, who will keep her main objectives
supporting the general strategy of BioSenic.as efficiently as
always, but keeping a day-to-day pace in accordance with her
general physical condition. We acknowledge her dedication, deep
insight and clear views on the positioning of our companies,
BioSenic and Medsenic. Véronique keeps all her duties in Medsenic
while serving now as a non-executive Board Member in
BioSenic.”.
About BioSenic
BioSenic is a leading biotech company
specializing in the development of clinical assets issued
from its Medsenic’s arsenic trioxide (ATO) platform. Key target
indications for the autoimmune platform include
graft-versus-host-disease (GvHD), systemic lupus erythematosus
(SLE), and now systemic sclerosis (SSc).
Following the merger in October 2022, BioSenic combined the
strategic positionings and strengths of Medsenic and Bone
Therapeutics. The merger specifically enables
Medsenic/Biosenic to develop an entirely new arsenal of various
anti-inflammatory and anti-autoimmune formulations using the
immunomodulatory properties of ATO/oral ATO (OATO).
BioSenic is based in the Louvain-la-Neuve
Science Park in Mont-Saint-Guibert, Belgium. Further information is
available at http://www.biosenic.com.
About the main Medsenic/BioSenic
technology platform
The ATO
platform provides derived active products with
immunomodulatory properties and fundamental effects on the
activated cells of the immune system. One direct application is its
use in onco-immunology to treat GvHD (Graft-versus-Host Disease) in
its chronic, established stage. cGvHD is one of the most common and
clinically significant complications affecting long-term survival
of allogeneic hematopoietic stem cell transplantation
(allo-HSCT).
Medsenic has been successful in a phase 2
trial with its intravenous formulation,
Arscimed®, which has orphan
drug designation status by FDA and EMA. The company is heading
towards an international phase 3 confirmatory study, with its new,
IP-protected, OATO formulation. Another selected target is
moderate-to-severe forms of systemic lupus erythematosus (SLE),
using the same oral formulation. ATO has shown good safety and
significant clinical efficacy on several affected organs (skin,
mucosae, and the gastrointestinal tract). Systemic sclerosis is now
full part of the clinical pipeline of Medsenic/BioSenic. This
serious chronic disease badly affects skin, lungs, or
vascularization, and has no current effective treatment.
Preclinical studies on pertinent animal models are positive, giving
good grounds to launch a phase 2 clinical protocol, using new
immunomodulatory formulations of APIs recognized to be active on
the immune system.
The company is currently focusing its
present R&D and clinical activities on a selective, accelerated
development of its autoimmune platform.
Note: The allogeneic cell therapy
platform-originating from the previous listed company Bone
Therapeutics company, may be of renewed interest by using isolated
and purified differentiated bone marrow Mesenchymal Stromal Cells
(MSCs) as a starting material for further isolation of passive or
active biological subcellular elements. Indeed, these cells may
provide new subcellular vesicles potentially able to deliver a
unique and proprietary approach to organ repair. BioSenic is now
involved in determining new patentable approaches in this complex
area of cell therapy.
For further information, please
contact:
BioSenic SA
François Rieger, PhD, CEO
Tel: +33 (0)671 73 31 59
investorrelations@biosenic.com
Certain statements, beliefs and opinions in
this press release are forward-looking, which reflect the company
or, as appropriate, the company directors’ current expectations and
projections about future events. By their nature, forward-looking
statements involve a number of risks, uncertainties and assumptions
that could cause actual results or events to differ materially from
those expressed or implied by the forward-looking statements. These
risks, uncertainties and assumptions could adversely affect the
outcome and financial effects of the plans and events described
herein. A multitude of factors including, but not limited to,
changes in demand, competition and technology, can cause actual
events, performance or results to differ significantly from any
anticipated development. Forward looking statements contained in
this press release regarding past trends or activities should not
be taken as a representation that such trends or activities will
continue in the future. As a result, the company expressly
disclaims any obligation or undertaking to release any update or
revisions to any forward-looking statements in this press release
as a result of any change in expectations or any change in events,
conditions, assumptions or circumstances on which these
forward-looking statements are based. Neither the company nor its
advisers or representatives nor any of its subsidiary undertakings
or any such person’s officers or employees guarantees that the
assumptions underlying such forward-looking statements are free
from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the forecasted
developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.
Biosenic (EU:BIOS)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Biosenic (EU:BIOS)
Historical Stock Chart
Von Dez 2023 bis Dez 2024